Ralph Weichselbaum and colleagues explore how enhancing innate and adaptive immunity by combining radiotherapy and immune therapy could tip the balance of the host immune response to promote cure. This is a summary, by Janet [more]
Focusing on the UK situation, Willie Hamilton and colleagues investigate why speeding up diagnosis of symptomatic cancers may be important, how to achieve it, who to focus on and where, and finally how much such [more]
Sriram Venneti and colleagues examine non-invasive metabolic imaging strategies that can be used to interrogate some of the genomic alterations in brain tumours, with the ultimate goal of informing patient management. This is an abridged [more]
Male breast cancer is almost always oestrogen receptor positive, and is traditionally treated in line with guidelines for treating hormone-sensitive breast cancers in postmenopausal women. Ian Fentiman questions the rationale for this approach, pointing to [more]
Bradford Hesse and colleagues explore insights gained from over a decade of data gathered by the US National Cancer Institute to monitor changes in the communication environment regarding cancer-related information. This is an abridged version [more]
Combining the complementary approaches of HPV vaccination and screening could accelerate declines in the burden of cervical cancer argue Xavier Bosch and colleagues. They are proposing the HPV-FASTER protocol as a way to achieve it. [more]
Treatment of advanced-stage ovarian cancer should comprise optimal debulking surgery followed by adjuvant intraperitoneal chemotherapy. Steven Narod, from Women’s College Research Institute, Toronto, Canada, argues that widespread adoption of this model would increase cure rates [more]
Standards of care are not yet defined for patients with recurrent glioblastoma. In this critical review, Katharina Seystahl and colleagues summarise the available literature for patients with recurrent (progressive) glioblastoma treated with repeat surgery, re-irradiation, [more]
Repurposing established drugs for oncology patients offers the potential to deliver cheaper and faster drug development. This could help close the widening gap between patient expectations and healthcare budgets, as the cost of medical anticancer [more]
With a five-year overall survival of less than 5%, there is an urgent need to explore new treatment paradigms for pancreatic cancer, including targeting stroma cells, cancer stem cells and metabolic pathways. Ignacio Garrido-Laguna and [more]
The impact chemotherapy can have on the ability to think clearly is well recognised. Less is known, however, about the cognitive effect of endocrine therapies, which in the adjuvant breast cancer setting are being prescribed [more]
Over the past decade, genetic testing for rare inherited mutations, such as BRCA1 and BRCA2 mutations, has been successfully incorporated into clinical practice. Next-generation sequencing of cancer-susceptibility genes and entire tumour genomes has transformed cancer [more]
Although radiotherapy is a key component of cancer treatment, provision of this modality is not immune to limits placed on health-care expenditure. Recent studies suggest European radiation oncology resources will generally be insufficient to meet [more]